MJN Neuroserveis
Wearable earpiece using AI to predict epileptic seizures.
- B2C
- manufacturing
- marketplace & ecommerce
- subscription
- health
- medical devices
- biotechnology
- hardware
- big data
- deep tech
- machine learning
- nanotech
- computer vision
- connected device
- mobile app
- iot internetofthings
- artificial intelligence
- dt and ls
- biotechnology
- horizon europe
- sustainable development goals
- core ai
- ai applications
- eit ecosystem
- predictive analytics
- wearable
- neurology
- digital care
- eit health
- patient care
- direct-to-consumer
- ai model layer
- eit kic partners
- medical diagnostics
- health information
- bridgehead europe (eit health)
- epilepsy
- bridgehead europe 2020 (eit health)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
€1.0k | Support Program | ||
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 28 % | (89 %) | 2732 % | 226 % | 260 % | (83 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (412 %) | (394 %) | (6178 %) | (83 %) | 40 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (309 %) | (329 %) | (2762 %) | (83 %) | (26 %) | 43 % | (79 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
MJN Neuroserveis, founded in 2014, is a medical device company that developed mjn-SERAS, a wearable device for predicting epileptic seizures. The company was started by David Blánquez, an engineer and father of a child with epilepsy, along with Salva Gutiérrez, an economist, and Xavier Raurich, an electronic engineer. Blánquez's personal experience with his daughter's condition was the primary motivation for creating a solution to improve the quality of life for people with epilepsy.
The company's core product, mjn-SERAS, is a non-invasive, custom-fit earpiece that functions like a discreet hearing aid. It continuously records the brain's electrical activity (ear-EEG) and uses personalized artificial intelligence algorithms to analyze the data in real-time. The device can predict the onset of a seizure 1 to 3 minutes before it occurs, sending an alert to the user's smartphone and designated caregivers via a connected app. This warning allows the individual to move to a safe place, mitigating the risk of injury. The system also logs seizure data, which can be shared with neurologists to improve monitoring and treatment.
The business operates in the MedTech market, serving individuals with drug-resistant epilepsy. The business model involves the sale of the CE-marked medical device. The company has secured funding through various channels, including crowdfunding, public grants from entities like ENISA and the European Commission, and venture capital. MJN Neuroserveis has also expanded its focus to develop solutions for other neurological conditions, such as mjn-DREAMER for the early detection of Alzheimer's disease and mjn-VISOR for outpatient brain activity monitoring.
Keywords: epilepsy prediction, wearable medical device, ear-EEG, seizure detection, artificial intelligence, neurotechnology, digital health, epilepsy management, seizure alert system, neurological disorders, mjn-SERAS, David Blánquez, MedTech, non-invasive monitoring, brain activity sensor, AI algorithms, patient safety, predictive analytics, Alzheimer's detection, remote patient monitoring